Sign In
Buy TIL
$7.12
-0.0200 (-0.280%)
At Close: Jul 31, 2026
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
01:06pm, Thursday, 29'th May 2025
Instil Bio (TIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
11:00am, Thursday, 29'th May 2025
The consensus price target hints at a 343.6% upside potential for Instil Bio (TIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
07:09am, Sunday, 25'th May 2025
Key catalyst: Phase 2 data from China in first-line NSCLC expected in 2H 2025, with enrollment completion projected for Q3 2025. The global non-small cell lung cancer therapeutics market size is proje
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced
Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 13'th May 2025
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
07:09am, Tuesday, 04'th Mar 2025
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
07:00am, Tuesday, 14'th Jan 2025
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
02:06pm, Tuesday, 07'th Jan 2025
Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
05:00am, Sunday, 01'st Dec 2024
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharm
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinica
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
04:56am, Wednesday, 25'th Sep 2024
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soar
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
12:31pm, Monday, 16'th Sep 2024
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
12:26pm, Monday, 16'th Sep 2024
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the glo
